Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Oct 17 - Oct 22
It is a dual GLP-1 and GIP receptor agonist, meaning it activates two incretin hormone pathways simultaneously
Proper regulatory compliance improves the credibility and reproducibility of scientific research
It is not clinical evidence and should not replace professional medical advice
In short-term studies, some obese people injected with AOD-9604 experienced headaches, chest tightness, palpitations, and euphoric feelings, which were considered to be drug-related
Key cited studies: Heffernan M et al
US$ 20.90
US$ 26.62
US$ 23.60
US$ 20.20
US$ 25.94
US$ 20.42
US$ 27.87
US$ 22.64
/assets/images/provider/photos/2657131.jpg)
US$ 28.78
